Study points to potential new therapies for cancer and other diseases

Researchers at The Scripps Research Institute (TRSI) are fuelling the future of cancer treatment by improving a powerful tool in disease defence: the body's immune system. By revealing a novel but widespread cell signalling process, the scientists may have found a way to manipulate an important component of the immune system into more effectively fighting disease.

The study, recently published online ahead of print by the journal Blood, shows that disabling a particular enzyme, called ItpkB, in mice improves the function of a type of immune cell called Natural Killer cells.

''This is an exciting finding because it could possibly lead to the development of drugs that improve Natural Killer cell function,'' said TSRI Associate Professor Karsten Sauer, PhD, who led the study. "Natural Killer cells have gained clinical interest as innovative biological therapeutics for certain cancers and also in certain infectious diseases.''

The body's 'SWAT team'
Natural Killer cells patrol the body and detect characteristic alterations on the surface of cancer cells or virus-infected cells. Through a complicated and little understood signalling machinery - a domino effect of molecular reactions in a cell that ultimately produces a certain signal - Natural Killer cells then destroy such ''stressed'' cells.

Compared to other types of immune cells, Natural Killer cells kill these cells quickly. This makes Natural Killer cells important early responders of the immune system. Not surprisingly, researchers have explored engaging this "SWAT team" of the body therapeutically, particularly in blood cancers.

However, to date, the therapeutic efficacy of Natural Killer cells has been limited. ''A key bottleneck is our limited understanding of signaling mechanisms that dampen Natural Killer cell function,'' Sauer said.